Clinical Trial Update: Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. [Phase 3]

View source ↗

Summary

Phase III study of ruxolitinib in early myelofibrosis with high molecular risk mutations was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelofibrosis With High Molecular Risk Mutations | Phase 3 | Status: TERMINATED | Results posted: 2019-08-16